Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging

Sponsor
Ruijin Hospital
Study ID
NCT07554742
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to use Claudin 18.2 (CLDN18.2)-targeted positron emission tomography (PET) imaging technology to evaluate its detection efficacy and diagnostic threshold for CLDN18.2-positive pancreatic cancer and gastric/gastroesophageal junction cancer, analyze the quantitative value of PET parameters in CLDN18.2 expression and their correlation with prognosis, and provide a basis for the precise selection of CLDN18.2-targeted therapy.

Key Dates

First listed
Apr 28, 2026
Start date
Apr 15, 2026
Status verified
Apr 2026
Primary completion
Mar 31, 2029
Completion
Mar 31, 2029

Study Design

Enrollment
64 participants (estimated)

Arms

  • Arm: participants with pancreatic cancer, gastric cancer or GEJ cancer and CLDN18.2 expression
    Participants with pancreatic cancer, gastric cancer or gastroesophageal junction (GEJ) cancer and immunohistochemistry (IHC)-confirmed CLDN18.2 expression at any level.

Primary Outcome Measure

Standardized uptake value(SUV) [ Time Frame: Baseline and preoperative assessment at 3 weeks before surgery ]

Central Contacts

Find similar trials

Nationwide
Gastric cancer trialsPancreatic cancer trialsOncology trialsGI oncology trials

Related Studies